---
title: "Major Insider Move at OrthoPediatrics Signals a Big Shift"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297721995.md"
description: "OrthoPediatrics director David R. Pelizzon sold 336,831 shares for $7.76 million on Sept 1, 2026. This insider move contrasts with the company's strong Q2 performance, which saw improved revenue, EBITDA, and raised guidance. Despite positive analyst sentiment and a 'Buy' technical signal, TipRanks AI rates KIDS as Neutral due to ongoing losses and negative free cash flow."
datetime: "2026-09-02T02:08:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297721995.md)
  - [en](https://longbridge.com/en/news/297721995.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297721995.md)
generator: "portal-rs"
---

# Major Insider Move at OrthoPediatrics Signals a Big Shift

New insider activity at OrthoPediatrics ( (KIDS) ) has taken place on September 1, 2026.

Director David R. Pelizzon has executed a significant insider transaction in OrthoPediatrics, selling a total of 336,831 shares of the company’s stock. The shares were sold for an aggregate value of $7,761,194, highlighting a sizable move in the company’s insider activity and potentially drawing attention from investors tracking executive and director trading patterns.

OrthoPediatrics’ stock reacted to a record Q2, with revenue, EBITDA, margins, and free cash flow all improving, and management raising multi‑year revenue guidance while reiterating EBITDA goals. Analysts lifted price targets mainly due to the strong Trauma & Deformity and OPSB growth, successful new product launches like 3P Hip, and confidence that scoliosis weakness and FX‑driven EPS headwinds are temporary timing and currency issues rather than demand problems.

**Spark’s Take on KIDS Stock**

According to Spark, TipRanks’ AI Analyst, KIDS is a Neutral.

The score is driven by strong technical momentum and a notably positive earnings update (raised revenue guidance, improving adjusted EBITDA, and a credible path toward free-cash-flow breakeven). These positives are tempered by weaker underlying financial performance (ongoing losses and negative free cash flow in TTM) and an unsupportive earnings-based valuation due to a negative P/E.

To see Spark’s full report on KIDS stock,  
 click here. 

**More about OrthoPediatrics**

**YTD Price Performance:** 31.25%

**Average Trading Volume:** 192,009

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $617.5M

### Related Stocks

- [KIDS.US](https://longbridge.com/en/quote/KIDS.US.md)

## Related News & Research

- [OrthoPediatrics director, 10% owner David R. Pelizzon disposes of USD 6.35 million in common shares](https://longbridge.com/en/news/298640456.md)
- [OrthoPediatrics (NASDAQ:KIDS) Sees Strong Trading Volume  - What's Next?](https://longbridge.com/en/news/298624585.md)
- [Is the AI bubble bursting?](https://longbridge.com/en/news/298981516.md)
- [Even hedge funds are dealing with AI slop](https://longbridge.com/en/news/299297081.md)
- [Instagram wants you to pay for its AI photo-editing filters](https://longbridge.com/en/news/298960174.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**